1. Home
  2. BIVI vs FLGC Comparison

BIVI vs FLGC Comparison

Compare BIVI & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIVI
  • FLGC
  • Stock Information
  • Founded
  • BIVI 2013
  • FLGC 2019
  • Country
  • BIVI United States
  • FLGC United States
  • Employees
  • BIVI N/A
  • FLGC N/A
  • Industry
  • BIVI Biotechnology: Pharmaceutical Preparations
  • FLGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • BIVI Health Care
  • FLGC Health Care
  • Exchange
  • BIVI Nasdaq
  • FLGC Nasdaq
  • Market Cap
  • BIVI 14.2M
  • FLGC 13.5M
  • IPO Year
  • BIVI N/A
  • FLGC 2021
  • Fundamental
  • Price
  • BIVI $1.50
  • FLGC $8.01
  • Analyst Decision
  • BIVI
  • FLGC Strong Buy
  • Analyst Count
  • BIVI 0
  • FLGC 1
  • Target Price
  • BIVI N/A
  • FLGC $156.00
  • AVG Volume (30 Days)
  • BIVI 119.4K
  • FLGC 26.6K
  • Earning Date
  • BIVI 11-11-2025
  • FLGC 11-05-2025
  • Dividend Yield
  • BIVI N/A
  • FLGC N/A
  • EPS Growth
  • BIVI N/A
  • FLGC N/A
  • EPS
  • BIVI N/A
  • FLGC N/A
  • Revenue
  • BIVI N/A
  • FLGC $39,649,000.00
  • Revenue This Year
  • BIVI N/A
  • FLGC N/A
  • Revenue Next Year
  • BIVI N/A
  • FLGC $10.48
  • P/E Ratio
  • BIVI N/A
  • FLGC N/A
  • Revenue Growth
  • BIVI N/A
  • FLGC N/A
  • 52 Week Low
  • BIVI $1.42
  • FLGC $7.37
  • 52 Week High
  • BIVI $38.50
  • FLGC $81.90
  • Technical
  • Relative Strength Index (RSI)
  • BIVI 29.30
  • FLGC 27.29
  • Support Level
  • BIVI $1.83
  • FLGC $8.73
  • Resistance Level
  • BIVI $1.80
  • FLGC $10.25
  • Average True Range (ATR)
  • BIVI 0.10
  • FLGC 1.47
  • MACD
  • BIVI -0.03
  • FLGC -0.39
  • Stochastic Oscillator
  • BIVI 14.79
  • FLGC 6.12

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

About FLGC Flora Growth Corp.

Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.

Share on Social Networks: